Scienture Holdings Inc

Scienture Holdings Inc (MEDS) Stock Analysis

$1.165

-0.053 (-4.51%)At close

Loading chart…
High
1.240
Open
1.200
VWAP
1.18
Volume
114.44K
Mkt Cap
18.51M
Low
1.130
Amount
134.84K
EV/EBITDA, TTM
0.00

DataMeds AI, Inc., formerly Wellgistics Health, Inc., is a holding company. It is engaged in health information technology (IT) that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units. The Company conducts its business through two wholly owned subsidiaries, Wood Sage, LLC and Wellgistics LLC, and two indirect subsidiaries, Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows clinical services to be connected to its health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, prescription price transparency, and provide additional concierge services.

AI analysis of Scienture Holdings Inc (MEDS)

Sell

TRxADE Health Inc (MEDS) is not a good buy right now due to significant financial losses and poor technical indicators. The current price is $1.17, with a 5-day change of -39.32% and a year-to-date change of -66.90%. The RSI is at 9.228, indicating that the stock is extremely oversold, but this does not guarantee a rebound. The main risk is the company's negative net income, which reached -$18,363,225 in Q2 2026, reflecting ongoing financial instability.

Valuation Metrics

The current forward P/E ratio for Scienture Holdings Inc (MEDS) is 0.00, compared to its 5-year average forward P/E of 21.83.

Forward P/E

Strongly Undervalued
5Y Average P/E
21.83
Current P/E
0.00
Overvalued
21.83
Undervalued
21.83

Forward EV/EBITDA

Strongly Overvalued
5Y Average EV/EBITDA
-0.01
Current EV/EBITDA
0.00
Overvalued
-0.01
Undervalued
-0.01

Forward P/S

Strongly Undervalued
5Y Average P/S
1.43
Current P/S
0.00
Overvalued
1.43
Undervalued
1.43

Events Timeline

2026-11-05 (ET)

10:00:00

DataMeds AI Signs MOU with Florida HMO

2026-11-03 (ET)

18:30:00

DataMeds AI Terminates Letter of Intent with Datavault AI

2026-11-02 (ET)

06:30:00

DataMeds AI Subsidiary Corexa Health Signs Drug Supply Agreement

2026-10-22 (ET)

08:30:00

Datavault AI Plans to Acquire 19.9% Stake in DataMEDS

08:00:00

DataMEDS Enters into Letter of Intent with Datavault AI

News

MEDS FAQ — answered by Alphio AI

DataMeds AI, Inc., formerly Wellgistics Health, Inc., is a holding company. It is engaged in health information technology (IT) that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units. The Company conducts its business through two wholly owned subsidiaries, Wood Sage, LLC and Wellgistics LLC, and two indirect subsidiaries, Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows clinical services to be connected to its health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, prescription price transparency, and provide additional concierge services. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

TRxADE Health Inc (MEDS) is not a good buy right now due to significant financial losses and poor technical indicators. The current price is $1.17, with a 5-day change of -39.32% and a year-to-date change of -66.90%. The RSI is at 9.228, indicating that the stock is extremely oversold, but this does not guarantee a rebound. The main risk is the company's negative net income, which reached -$18,363,225 in Q2 2026, reflecting ongoing financial instability.

Community

More ↗
Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading